

used. The reduced dimensional data set is visualized in three dimensions using these novel algorithms. These visualized algorithms derive the first three principal components from Fisher's matrix and project the multidimensional data into three dimensional gene expression data space. Exploration of the reduced dimensional data set allows for the identification of discriminant genes that are either assembled into a predictive neural network, and/or selected for functional studies. These approaches have proved useful in recent studies conducted by Dr. Hilakivi-Clarke (Georgetown University, Lombardi Cancer Center) in identifying genes affected by timing of dietary exposures on breast cancer risk and are the preferred approaches for this study.

Georgetown University, Lombardi Cancer Research Center Animal Core Facility has an AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) accredited animal facility where the animals can be housed. Georgetown can provide the software, hardware, and sophisticated, statistically principled data mining tools. In addition, Georgetown University is already collaborating in an on-going women study in Finland measuring hormone and adipokine levels from blood samples.

This is a sole source award to Lombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University, Washington, DC.

II. Award Information/Funds Available

Awards are made under the authorization of section 301 of the Public Health Service Act (PHS Act) (42 U.S.C. 241), as amended, and under Federal regulations at 42 CFR part 52 and 45 CFR parts 74 and 92.

A. Award Amount

The total amount CVM expects to award is \$100,400 in the first year and \$104,400 in the second year for a total award of \$204,800; total award amount includes direct and indirect costs.

B. Length of Support

The project period will be from September 2009 to August 31, 2011. The first budget period will be from September 2009 to August 31, 2010.

The second year award will depend on the availability of funds and recipient approved performance.

III. Paper Application, Registration, and Submission Information

To submit a paper application in response to this FOA, applicants should first review the full announcement

located at <http://www.fda.gpo/cvm>. Persons interested in applying for a grant may obtain application forms and instructions at <http://grants.nih.gov/grants/forms.htm>. For all paper application submissions, the following steps are required:

- Step 1: Obtain a Dun and Bradstreet (DUNS) Number
- Step 2: Register With Central Contractor Registration (CCR)
- Step 3: Register With Electronic Research Administration (eRA) Commons

Steps 1 (DUNS Number) and 2 (CCR), in detail, can be found at http://www07.grants.gov/applicants/organization_registration.jsp. Step 3 (eRA Commons), in detail, can be found at <https://commons.era.nih.gov/commons/registration/registrationInstructions.jsp>.

After you have followed these steps, submit paper applications to the Grants Management Contact at the following address:

Gladys M. Bohler, Division of Acquisition Support and Grants (HFA-500), Food and Drug Administration, 5630 Fishers Lane, rm. 2105, Rockville, MD 20857, 301-827-7168, FAX: 301-827-7101, e-mail: gladys.bohler@fda.hhs.gov.

Dated: September 17, 2009.

David Horowitz,

Assistant Commissioner for Policy.

[FR Doc. E9-22848 Filed 9-22-09; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Dental & Craniofacial Research; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel; Review of R34 Clinical Trial

Pilot Applications PAR-08-195 and R01 PA-07-070 Applications.

Date: October 30, 2009.

Time: 10:30 a.m. to 1:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Rebecca Wagenaar Miller, PhD, Scientific Review Officer, Scientific Review Branch, National Inst of Dental & Craniofacial Research, National Institutes of Health, 6701 Democracy, Rm 666, Bethesda, MD 20892, 301-594-0652, rwagenaar@mail.nih.gov.

Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)

Dated: September 16, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-22969 Filed 9-22-09; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Microbiology, Infectious Diseases and AIDS Initial Review Group; Microbiology and Infectious Diseases Research Committee.

Date: October 6, 2009.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: The Legacy, 1775 Rockville Pike, Rockville, MD 20852.

Contact Person: Michelle M. Timmerman, PhD, Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, Room 2217, 6700B Rockledge Drive, MSC-7616, Bethesda, MD 20892-7616. 301-451-4573. timmermanm@niaid.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing